dupilumab, by competitively inhibiting IL-4 and IL-13 binding to IL-4Rα, attenuates Th2 cytokine-mediated enhancement of IL-8 production induced by dsRNA or viral infection in epithelial cells. Here, IL4 is linked to viral infectious disease.